Antineoplaston Therapy in Treating Children With Primitive Neuroectodermal Tumors
Status:
Completed
Trial end date:
2005-02-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Current therapies for children with primitive neuroectodermal tumors that have not
responded to standard therapy provide very limited benefit to the patient. The anti-cancer
properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of
children with primitive neuroectodermal tumors that have not responded to standard therapy.
PURPOSE: This study is being performed to determine the effects (good and bad) that
Antineoplaston therapy has on children (> 6 months of age) with primitive neuroectodermal
tumors that has not responded to standard therapy.